Clinical Trials
National/International Multicenter Clinical Trials
Science 37 Screening Colonoscopy:
Title: REEMPT CRC: Prevention of Colorectal Cancer Through Multiomics Blood Testing
Sponsor: Freenome Holdings, Inc.
Start Date: Aug 2021 (tentative)
Status: Upcoming
Science 37 NASH:
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of STUDY DRUG in Subjects with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Sponsor: Science 37
Start Date: TBD
Status: Upcoming
MET642: A Sustained FXR Agonist with Best-in-Class Potential for the Treatment of NASH:
Title: Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients with Nonalcoholic Steatohepatitis (NASH)
Sponsor: Metacrine, Inc
Start Date: Mar 2021
End Date: Dec 2021
Status: Enrollment closed
NASH PASS a national registry of NASH:
Title: NASH PASS: A population based epidemiological NAFLD/NASH registry and research project
Sponsor: ProSciento, Inc
Start Date: Sep 2021
End Date: Jul 2021
Status: Ended until 2022
Regeneron Liver Biopsy:
Title: A study to evaluate narrow gauge core needle biopsy samples for measuring gene expression in the liver in patients with nonalcoholic steatohepatitis
Sponsor: Regeneron Pharmaceuticals, Inc.
Start Date: December 2020
End Date: May 2021
Status: Closed
AstraZeneca GLP-1 agonist in treatment of NASH:
Title: A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH)
Sponsor: MedImmune Limited, a wholly owned subsidiary of AstraZeneca
Start Date: Feb 2020
End Date: March 2021
Status: Closed